{"filing":{"accession_number":"0001193125-26-331522","cik":"0001745999","ticker":"BEAM","company_name":"Beam Therapeutics Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"beam-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-20260804.htm"},"events":[{"id":23864,"run_id":21585,"accession_number":"0001193125-26-331522","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Beam Therapeutics' second quarter 2026 financial results. The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026\" and includes condensed consolidated balance sheet and statement of operations data showing net loss of $122.7 million for Q2 2026 versus $102.1 million in Q2 2025, along with cash position, R\u0026D and G\u0026A expenses, and cash runway guidance through mid-2029. This is a material disclosure affecting investor assessment of the registrant's financial condition.","company_name":"Beam Therapeutics Inc.","ticker":"BEAM","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24214,"accession_number":"0001193125-26-331522","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Beam Therapeutics' second quarter 2026 financial results. The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026\" and includes condensed consolidated balance sheet and statement of operations data showing net loss of $122.7 million for Q2 2026 versus $102.1 million in Q2 2025, along with cash position, R\u0026D and G\u0026A expenses, and cash runway guidance through mid-2029. This is a material disclosure affecting investor assessment of the registrant's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:22.020789+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24214,"accession_number":"0001193125-26-331522","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Beam Therapeutics' second quarter 2026 financial results. The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026\" and includes condensed consolidated balance sheet and statement of operations data showing net loss of $122.7 million for Q2 2026 versus $102.1 million in Q2 2025, along with cash position, R\u0026D and G\u0026A expenses, and cash runway guidance through mid-2029. This is a material disclosure affecting investor assessment of the registrant's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:22.020789+00:00","company_name":"Beam Therapeutics Inc.","ticker":"BEAM","filing_date":"2026-08-04"}]}